Albiorex

Albiorex, founded in 2007 by C. Randall Harrell, operated in the biotechnology sector with a focus on regenerative medicine. The company, which is now defunct, was headquartered in Palm Harbor, Florida. It concentrated on acquiring and developing embryonic stem cell-free regenerative products specifically for the aesthetics and wound care markets. The company's business strategy revolved around commercializing high-value dermal fillers and wound care products that utilized human-based biomaterials instead of animal or synthetic components.

The core of Albiorex's offering was its proprietary platform technology that used and modified human collagen while aiming to retain its bioactive properties. A key product developed from this platform was Humallagen®, which was marketed as a dermal filler and for wound care applications. The main value proposition for healthcare providers was the use of products with regenerative qualities to address unmet clinical needs without embryonic stem cells. The company secured approximately $2.02 million in a single seed funding round on January 2, 2008, to support its operations and development. Corporate filings indicate the entity became inactive in subsequent years.

The founder, C. Randall Harrell, who also served as CEO, has been involved in at least one other company in the regenerative medicine space, named Regener-Eyes. Keywords: biotechnology, regenerative medicine, dermal fillers, wound care, human collagen, biomaterials, aesthetics, Humallagen, C. Randall Harrell, defunct startup